Compare Nasdaq100 ETF (QQQ) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Nasdaq100 ETF trades at $719.7 (market cap $501.32B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Nasdaq100 ETF is far larger — about 66.7× Spyre Therapeutics Inc. Common Stock's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 163 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| QQQ | SYRE | |
|---|---|---|
Market Cap | $501.32B | $7.52B |
Volume | 28,524,918 | 1,441,031 |
52-Week High | $759.66 | $108.92 |
52-Week Low | $558.34 | $22.18 |
Typical Hold Time | 163 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $728.95, down 2.28% today amid broader market pressure. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. The ETF faces mixed analyst sentiment with a 50/50 split between buy and sell recommendations. Recent news highlights concerns about AI market sustainability and Fed rate impacts, though historical patterns suggest potential post-midterm election strength.
QQQ's concentrated tech exposure offers growth potential through AI-driven innovation but carries valuation risks amid elevated market levels. Key risks include interest rate sensitivity and sector concentration, while institutional expansion through new international ETFs signals long-term confidence in the innovation theme.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
